ABSTRACT
Patients receiving chronic anticoagulation therapy pose a clinical challenge when
therapy needs to be interrupted for surgical or invasive procedures. Maintaining anticoagulation
places them at risk of serious bleeding complications, whereas discontinuing anticoagulation
puts them at risk of thromboembolic complications. The main patient groups that may
require a periprocedural alternative to oral anticoagulation include patients with
prosthetic heart valves, atrial fibrillation, and hypercoagulable states and those
with chronic venous thrombosis undergoing surgery. Currently, there is little consensus
on appropriate perioperative management of patients on long-term warfarin therapy.
This article is an attempt to bring together all the available data on periprocedural
bridging to assess the available options for patients undergoing surgical procedures
and to provide a rationale for using low-molecular-weight heparins (LMWHs) while individualizing
the risks versus benefits in a given patient population.
KEYWORDS
Anticoagulants - bridging - warfarin - prosthetic heart valves - hypercoagulability
- thrombosis - bleeding
REFERENCES
- 1
Kearon C, Hirsh J.
Management of anticoagulation before and after elective surgery.
N Engl J Med.
1997;
336
1506-1511
- 2 Lassen M, Borris L. Prevention in orthopedic surgery and trauma. In: Hull R, Pineo
G Disorders of Thrombosis Philadelphia; WB Saunders 1996: 209-216
- 3
Travis S, Wray R, Harrison K.
Perioperative anticoagulant control.
Br J Surg.
1989;
76
1107-1108
- 4
Wahl M.
Dental surgery in anticoagulated patients.
Arch Intern Med.
1998;
158
1610-1616
- 5
Sindet-Pedersen S, Ramstrom G, Bernvil S et al..
Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing
oral surgery.
N Engl J Med.
1989;
320
840-843
- 6
Stone L, Kline Jr O, Sklar C.
Intraocular lenses and anticoagulation and antiplatelet therapy.
J Am Intraocul Implant Soc .
1985;
11
165-168
- 7
McCormack P, Simcock P, Tullo A.
Management of the anticoagulated patient for ophthalmic surgery.
Eye.
1993;
7
749-750
- 8
Hall D, Steen W J, Drummond J et al..
Anticoagulants and cataract surgery.
Ophthalmic Surg.
1988;
19
221-222
- 9
Carter K, Miller K.
Phacoemulsification and lens implantation in patients treated with aspirin or warfarin.
J Cataract Refract Surg.
1998;
24
1361-1364
- 10
Narendran N, Williamson T.
The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery.
Acta Ophthalmol Scand.
2003;
81
38-40
- 11
Gerson L, Gage B, Owens D et al..
Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients
who take anticoagulants.
Am J Gastroenterol.
2000;
95
1717-1724
- 12
Van Os E, Kamath P, Gostout C et al..
Gastroenterological procedures among patients with disorders of hemostasis: evaluation
and management recommendations.
Gastrointest Endosc.
1999;
50
536-543
- 13
Spandorfer J.
The management of anticoagulation before and after procedures.
Med Clin North Am.
2001;
85
1109-1116
- 14
Dunn A, Turpie A.
Perioperative management of patients receiving oral anticoagulants: a systematic review.
Arch Intern Med.
2003;
163
901-908
- 15
Stein P, Alpert J, Bussey H et al..
Antithrombotic therapy in patients with mechanical and biological prosthetic heart
valves.
Chest.
2001;
119
220S-227S
- 16
Heit J.
Perioperative management of the chronically anticoagulated patient.
J Thromb Thrombolysis.
2001;
12
81-87
- 17
Fuster V, Ryden L, Asinger R et al..
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive
summary. A report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines and the European Society of Cardiology Committee
for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for
the Management of Patients With Atrial Fibrillation): developed in collaboration with
the North American Society of Pacing and Electrophysiology.
J Am Coll Cardiol.
2001;
38
1231-1266
- 18
Erkan D, Leibowitz E, Berman J et al..
Perioperative medical management of antiphospholipid syndrome: hospital for special
surgery experience, review of literature, and recommendations.
J Rheumatol.
2002;
29
843-849
- 19
Kadayifci A, Haznedaroglu I, Savas M.
Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis.
Am J Gastroenterol.
1997;
92
361-362
- 20
Spandorfer J, Lynch S, Weitz H et al..
Use of enoxaparin for the chronically anticoagulated patient before and after procedures.
Am J Cardiol.
1999;
84
478-480
- 21
Galla J, Fuhs B.
Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac
surgery.
J Am Coll Cardiol.
2000;
135(Suppl 2)
531A
- 22
Ferreira I, Dos L, Tornos P et al..
Experience with enoxaparin in patients with mechanical heart valves who must withhold
acenocumarol.
Heart.
2003;
89
527-530
- 23
Tinmouth A, Morrow B, Cruickshank M et al..
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk
of thrombosis.
Ann Pharmacother.
2001;
35
669-674
- 24
Wilson S, Morgan J, Gray L.
A model for perioperative outpatient management of anticoagulation in high-risk patients:
an evaluation of effectiveness and safety.
Can J Hosp Pharm.
2001;
54
269-277
- 25
Turpie A, Johnson J.
Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin
(dalteparin).
Can J Cardiol.
2000;
16(Suppl F)
149F
- 26
Johnson J, Turpie A.
Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin.
Thromb Haemost.
1999;
82 (Suppl)
62-63 (abst)
- 27
Montalescot G, Polle V, Collet J et al..
Low molecular weight heparin after mechanical heart valve replacement.
Circulation.
2000;
101
1083-1086
- 28
Nutescu E, Helgason C.
Outpatient dalteparin peri-procedure bridge therapy in patients maintained on long
term warfarin.
Stroke.
2001;
32
328-329 (abst)
- 29
Ansell J, Dalen J, Bussey H et al..
Managing oral anticoagulant therapy.
Chest.
2001;
119(Suppl)
22S-38S
Syed M JafriM.D.
Department of Cardiology, Henry Ford Hospital
2799 W. Grand Boulevard, Detroit, MI 48202
eMail: sjafri2@hfhs.org